Readers of this blog will know that I've commented several times on the trials and tribulations of various treatments for non-small cell lung cancer therapies - mostly that they've failed to meet their endpoints in pivotal phase 3 clinical trials.
Yesterday, ArQule announced a more successful result for its ARQ 197 plus erlotinib in a phase 2 trial. Sally Church does a great job discussing the mechanism of this particular treatment and its merits (or lack thereof). As Derek Lowe, in his blog In the Pipeline, frequently reminds us, there is a big difference between a phase 2 and phase 3 trial. We'll see how this pans out further down the pipeline.
In the meantime, follow the link below to Sally's site for a more thorough discussion of the ARQ 197 molecule.
« New World New Models | Main | Got Melamine? Testers Step Up »
03/31/2010
ArQule's ARQ 197 plus erlotinib has mixed early data in lung cancer
| | |
TrackBack
TrackBack URL for this entry:
http://www.typepad.com/services/trackback/6a0120a77f675b970b0133ec5c045d970b
Listed below are links to weblogs that reference ArQule's ARQ 197 plus erlotinib has mixed early data in lung cancer:
Comments
You can follow this conversation by subscribing to the comment feed for this post.
The comments to this entry are closed.
Recent Posts
- Mythbusters: Biotech Venture Capital
- Pharma R&D Spending vs Other Industries
- Innovation as Illustrated by Beer
- Global Biosimilar Market Report 2013
- The Outcomes Era
- Latest Myriad Case Commentary
- Pharma Need for Adapting to Change
- US Drug Market Contracts for First Time - EVER!
- R&D Spending may not be ALL Bad
- Myriad BRCA Test Cost is In-Line
Search
Archives
- May 19, 2013 - May 25, 2013
- May 12, 2013 - May 18, 2013
- May 5, 2013 - May 11, 2013
- April 28, 2013 - May 4, 2013
- April 21, 2013 - April 27, 2013
- April 14, 2013 - April 20, 2013
- April 7, 2013 - April 13, 2013
- March 31, 2013 - April 6, 2013
- March 24, 2013 - March 30, 2013
- March 17, 2013 - March 23, 2013
Categories
- AIDs
- Animal Health
- Antibody Drug Conjugates
- Brazil News
- Business Model
- Cell Engineering
- China news
- Clinical Results
- CNS Therapies
- Conservative Curmudgeon Palaver
- Current Events
- Development Funding & Investment
- Drug Development
- Economics
- Ethics
- Facility News
- FDA & EU Approvals
- Gene Therapy
- Generics & Biosimilars
- Government Policy
- Healthcare Reform
- India News
- Innovation
- Korea News
- Liberal Altruisim
- Manufacturing Challenges
- Market Data & Facts & Research
- Market Rumors
- Mergers & Acquisitions
- Oncology
- OpEx and Lean
- Orphan, Neglected & Rare Diseases
- Outsourcing
- Patents & Legal
- Personalized Medicine
- Process Development
- Product Licensing/Acquisition
- Product Recalls/Warning Letters
- Quality Management Systems
- R&D Changes & Trends
- Random Fun Stuff
- Raw Material Detectives
- Raw Material Testing
- Regenerative Medicine & Stem Cells
- Regulatory Affairs & Policy
- Reimbursement & 3rd Party Payers
- Risk Mitigation
- RNAi therapeutics
- Russia News
- Science & Technology
- Supply Chain Management
- Trade Policy
- Trade Shows, Seminars, & Webinars
- Translational Medicine
- Vaccines & Virus
- Venture Capital
- Virtual Biotech's
- Weblogs & Websites
- Whitepapers
The FDA today (April 23rd) did approve use of OSI's Tarceva as a treatment for metastatic NSCLC as a maintenance therapy.
http://www.genengnews.com/news/bnitem.aspx?name=80510156
Posted by: Bruce Lehr | 04/23/2010 at 05:59 PM